15 Participants Needed

VIR-3434 for Hepatitis B

JF
JC
Overseen ByJiayun Chen
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: University Health Network, Toronto
Must be taking: Nucleos(t)ide therapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a Phase II Investigator-Initiated Study to understand the vaccinal effect of HBsAg monoclonal Ab VIR-3434 in chronic hepatitis B infection.The purpose of this study is to test VIR-3434, an experimental drug that specifically targets the HBsAg of hepatitis B virus, to clear it from the body.This is an open label study and there is no placebo used in this study. All participants will receive the VIR-3434 for 48 weeks and then follow up in the study for 48 weeks. A total duration of approximately 104 weeks including screening period for the entire study.

Do I need to stop my current medications to join the trial?

The trial does not specify if you need to stop your current medications, but it requires that you have been on stable nucleos(t)ide therapy for more than a year.

Who Is on the Research Team?

JF

Jordan Feld, MD, MPH

Principal Investigator

University Health Network, Toronto

Are You a Good Fit for This Trial?

This trial is for individuals with chronic hepatitis B. Participants will be involved in the study for about 104 weeks, receiving VIR-3434 weekly for the first 48 weeks and then being followed up for another 48 weeks.

Inclusion Criteria

Quantitative HBsAg 500 - 10,000 IU/mL
I am not pregnant, breastfeeding, and agree to use effective birth control during the study.
I am not pregnant or I am postmenopausal.
See 9 more

Exclusion Criteria

estimated Glomerular Filtration Rate (eGFR) < 45 cc/min
Bilirubin > 40 µmol/L
I have a history of severe liver disease.
See 20 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive VIR-3434 300 mg subcutaneous injection every 4 weeks for 48 weeks

48 weeks
12 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

48 weeks
12 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • VIR-3434
Trial Overview The trial is testing VIR-3434, an experimental drug aimed at targeting and clearing the HBsAg of hepatitis B virus from the body. It's a Phase II study where all participants receive the actual medication without any placebo.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: VIR-3434Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials
1,555
Recruited
526,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security